- MDV3100 Continues to Show Encouraging and Durable Anti-Tumor Activity and
Dose Escalation Continues - - Results Presented at the 20th EORTC-NCI-AACR Symposium on Molecular
Targets and Cancer Therapeutics -
GENEVA and SAN FRANCISCO, Oct. 22 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new data from an ongoing Phase 1-2 clinical trial demonstrating that the Company's novel androgen receptor antagonist MDV3100 continues to show promising safety and efficacy results. The data showed encouraging and durable anti-tumor activity in the three expanded dose groups tested thus far, as measured by prostate specific antigen (PSA) declines, radiographic findings, circulating tumor cell (CTC) changes, and time on treatment. MDV3100 has been generally well tolerated, with no reports of serious adverse events deemed related to MDV3100. Dose escalation in the trial is continuing.
"The tolerability and the anti-tumor activity seen with MDV3100 after six months of treatment remains encouraging," said Howard Scher, M.D., principal investigator of the trial and chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center. "The trial continues to enroll rapidly and additional data will further clarify the potential of MDV3100 as a treatment option for patients with castration-resistant prostate cancer, who have a poor prognosis and for whom treatment options are limited."
MDV3100 Trial Design and Results to Date
The ongoing Phase 1-2 trial is an open-label U.S. dose-escalation study
in prostate cancer patients who have failed standard hormonal therapies. To
|SOURCE Medivation, Inc.|
Copyright©2008 PR Newswire.
All rights reserved